US biotech Novavax has begun a phase 1 study of its coronavirus vaccine, as the number in clinical development reached double figures. The World Health Organization has been keeping tabs on ...

Novavax’s COVID-19 vaccine produced higher levels of neutralising antibodies than produced by recovered patients in an early trial, paving the way for a phase 3 trial and potential approval by ...

After two years characterized by layoffs, pipeline reorganizations, FDA delays and clinical holds, Novavax CEO John Jacobs ...

The Company has achieved a milestone associated with its Phase 2/3 clinical trial for its COVID-19 vaccine in children, triggering the first $50 million milestone payment from Sanofi. Novavax ...

The upfront payments are generous given the speculative value of Novavax's stand-alone adjuvanted COVID-19 vaccine. This is particularly true in view of the heavy expense Novavax endured in ...

Read Also: Why Novavax Stock Is Volatile This Week The news also intensified concerns about diminishing COVID-19 vaccine revenues and broader industry challenges as pandemic-driven demand ...

While the Novavax and the Sanofi GSK vaccines will not be part of the module, it will look at the circumstances surrounding the Covid-19 jab developed by Valneva. The UK had been due to receive ...

The Company has achieved a milestone associated with its Phase 2/3 clinical trial for its COVID-19 vaccine in children, triggering the first $50 million milestone payment from Sanofi. Novavax (NVAX) ...